---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-052142"
form_type: "8-K"
ticker: "DYN"
cik: "0001818794"
company_name: "Dyne Therapeutics, Inc."
filed_at: "2024-05-02T23:59:59+00:00"
generated_at: "2026-06-03T00:49:09.367957+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Dyne Therapeutics Q1 net loss $65.6M; cash $453.5M; clinical trials on track for H2 data

## Summary
- Net loss $65.6M ($0.81 per share) vs $44.2M ($0.78) in Q1 2023.
- Cash, equivalents and marketable securities $453.5M; expects funding through 2025.
- R&D expenses $44.5M (up 19% YoY); G&A expenses $24.6M (up 211% YoY) largely due to new CEO.
- John Cox appointed CEO and President in March 2024.
- Phase 1/2 ACHIEVE (DM1) and DELIVER (DMD) trials progressing; additional data expected H2 2024 with registrational cohorts by year-end.

## SEC filing metadata
- accession: 0000950170-24-052142
- form_type: 8-K
- ticker: DYN
- cik: 0001818794
- company_name: Dyne Therapeutics, Inc.
- filed_at: 2024-05-02T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818794/000095017024052142/0000950170-24-052142-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818794/000095017024052142/dyn-20240502.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-052142
- JSON: https://secwatch.observer/filing/0000950170-24-052142.json
- Plain text: https://secwatch.observer/filing/0000950170-24-052142.txt

## Key facts
- Earnings Releases
  Dyne Therapeutics, Inc. reported the quarter ended March 31, 2024 results: net income $65.6 million, or $0.81 per basic and diluted share, EPS $0.81 per basic and diluted share.
  - Period: the quarter ended March 31, 2024
  - Net income: $65.6 million, or $0.81 per basic and diluted share
  - EPS: $0.81 per basic and diluted share
  - Result: reported results
  source text: Net loss for the quarter ended March 31, 2024 was $65.6 million, or $0.81 per basic and diluted share.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1818794/000095017024052142/0000950170-24-052142-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.